Last update 01 Nov 2024

BMS-986315

Overview

Basic Info

Drug Type
Biological products
Synonyms
Target
NKG2A
Mechanism
NKG2A antagonists(killer cell lectin like receptor C1 antagonists)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
Non-Small Cell Lung Cancer
Inactive Indication
Advanced Malignant Solid NeoplasmNeuralgia
Originator Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Inactive Organization
NeuroTherapia, Inc.NeuroTherapia, Inc.Startup
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with BMS-986315
CTIS2022-503007-22-00 / Not yet recruiting
A Randomized, Double-Blind, Phase II Study of BMS-986315 and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) - CA0471009
NCT06094296 / CompletedPhase 2
A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04349267 / TerminatedPhase 1/2
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
100 Clinical Results associated with BMS-986315
Login to view more data
100 Translational Medicine associated with BMS-986315
Login to view more data
100 Patents (Medical) associated with BMS-986315
Login to view more data
100 Deals associated with BMS-986315
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 2
AU
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
27 Nov 2023
Non-Small Cell Lung CancerPhase 2
US
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
27 Nov 2023
Advanced Malignant Solid NeoplasmDiscovery
CA
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Jul 2020
Advanced Malignant Solid NeoplasmDiscovery
MX
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Jul 2020
Advanced Malignant Solid NeoplasmDiscovery
US
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free